Mizuho Maintains Outperform on Syndax Pharmaceuticals, Lowers Price Target to $43

Mizuho analyst Salim Syed maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Outperform and lowers the price target from $45 to $43.